All eyes on smartphone outlook after iPhone 12 debut. Check back at 4:30 p.m. ET for results.
|Bid||0.2300 x 0|
|Ask||0.2400 x 0|
|Day's Range||0.2300 - 0.2350|
|52 Week Range||0.2200 - 0.8600|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp.
Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021KELOWNA, BC / ACCESSWIRE / October 22, 2020 / Lexaria Bioscience Corp.
(OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology.